ABBV · News · 20261106N

Revenue Performance and Mix

AbbVie Inc. · 2026-11-06 · Importance 38 · Surprise 24

Skyrizi and Rinvoq together account for nearly half of AbbVie’s total sales, according to Trefis. The two immunology treatments are growing significantly faster than AbbVie overall and are offsetting declines in Humira and Imbruvica attributed to competition and pricing pressure. A separate Trefis report said the company’s growth depends largely on Skyrizi and Rinvoq, which are expected to contribute significantly to 2026 revenue.

Key facts

• Skyrizi and Rinvoq account for nearly half of AbbVie's total sales. source
• AbbVie expects Skyrizi and Rinvoq to contribute significantly to 2026 revenue. source
• AbbVie’s double-digit sales growth is a key factor for investors to assess for its continuation. source
• AbbVie trades at an adjusted earnings multiple around 21 based on 2026 forecasts. source
• Skyrizi and Rinvoq are growing significantly faster than AbbVie as a whole. source
• AbbVie's sales of Humira and Imbruvica are declining due to competition and pricing pressures. source
• AbbVie’s Vraylar and Humira sales are declining. source